Biotech firm signs $700M schizophrenia drug deal with Merck

01/3/2008 | Reuters

Addex Pharmaceuticals SA today announced it is collaborating with U.S.-based Merck & Co. to develop ADX63365, Addex's drug for schizophrenia. The deal grants the Swiss biotech firm $22 million upfront and makes it eligible for up to $680 million in milestone payments.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID